AGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Agilon Health Inc (AGL) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant negative sentiment due to ongoing legal investigations, declining price trends, and weak financial performance. Additionally, there are no strong technical or proprietary trading signals to support a buy decision.
The MACD histogram is positive at 0.039 and expanding, indicating slight bullish momentum. However, RSI at 66.673 is neutral, and moving averages are converging, showing no clear trend. The stock is trading near resistance levels (R1: 0.684), with a high probability of further downside (-5.31% in the next week).
Hedge funds and insiders are increasing their holdings significantly, with hedge fund buying up 1326.49% and insider buying up 490.98% over recent periods. Additionally, the Centers for Medicare & Medicaid Services' new LEAD model is seen as a positive for value-based care providers like Agilon Health.
Multiple class action lawsuits and investigations into alleged financial misrepresentation are creating significant negative sentiment. Recent price target downgrades from analysts and a Q4 earnings miss further weigh on the stock. The stock's price is down significantly in pre-market, regular market, and post-market trading.
In Q4 2025, revenue increased by 3.09% YoY to $1.57 billion. However, the company reported a net loss of $188.88 million, though this was an improvement of 78.54% YoY. EPS improved to -0.46, up 76.92% YoY, and gross margin improved significantly to -5.02%. Despite these improvements, the company remains unprofitable.
Recent analyst ratings are negative. Citi lowered the price target to 75c from 85c with a Neutral rating, and Barclays reduced the target to 50c from $1 with an Underweight rating. Analysts acknowledge some positive long-term potential but remain cautious due to near-term challenges.
